A cyclic dipeptide made from just two amino acids forms an ultra-stable hydrogel that enhances the anticancer activity of 5-fluorouracil through sustained release, lowering the effective dose needed.
>1 year stabilityThe cyclic dipeptide hydrogel remained intact for over a year without deformation — exceptional longevity for a peptide-based biomaterial
What the researchers found
A cyclic dipeptide made from leucine and S-benzyl cysteine (P1) self-assembled into a hydrogel at body temperature and physiological pH. The hydrogel was remarkably stable — lasting over a year without degradation, tolerating pH 6–12, and being thermoreversible.
When loaded with the cancer drug 5-fluorouracil (5FU), the hydrogel provided sustained drug release and significantly enhanced anticancer activity against colorectal cancer cells (HCT116), lowering the effective dose (IC50) of 5FU substantially. The dipeptide itself showed almost no toxicity to cancer cells even at high concentrations, making it a safe carrier material.
Why it matters
Cancer drugs like 5FU are effective but cause severe side effects because they hit healthy cells along with cancer cells. A delivery system that slowly releases the drug at the tumor site could improve efficacy while reducing side effects. This cyclic dipeptide hydrogel achieves exactly that — and it's made from just two amino acids, making it biocompatible, biodegradable, and potentially cheap to manufacture. The year-plus stability and body-temperature gelation make it particularly practical for clinical applications.
The numbers in context
2 amino acids (Leu + S-Bzl-Cys) · stable >1 year · pH 6–12 tolerance · thermoreversible · IC50 of 5FU significantly reduced · minimal cytotoxicity of carrier · nanofibrillar network structure · antiparallel β-sheet arrangement
How the study worked
Lab-based biomaterial study. Researchers synthesized cyclic dipeptide P1 and characterized its hydrogel using rheology (mechanical strength), atomic force microscopy, scanning electron microscopy, circular dichroism, FTIR spectroscopy, and ThT binding assay. Drug loading and release were tested with 5-fluorouracil, and anticancer activity was measured against HCT116 colorectal cancer cells in vitro.
Who was studied
In vitro study using HCT116 human colorectal cancer cells
What this study cannot tell us
Entirely in vitro — no animal or human testing. Drug release kinetics in a living body (with blood flow, immune response, and enzymatic degradation) may differ from lab conditions. No comparison with existing drug delivery systems. Tumor-targeting specificity was not assessed. Scalability of manufacturing was not addressed.
How to read the evidence
Preliminary evidence from in vitro biomaterial characterization and cell culture testing. The material properties are well-characterized with multiple analytical methods. However, anticancer efficacy is demonstrated only in cell culture with no animal or human data. The material needs extensive in vivo validation before clinical relevance can be assessed.
When this study was published
Published in 2022. Peptide-based hydrogels for drug delivery are an active and growing research field. This specific dipeptide design is relatively new and likely still being developed.
The bigger picture
Peptide-based hydrogels are an exciting frontier in drug delivery because they combine biocompatibility with self-assembling properties that create injectable gels at body conditions. This study adds a cyclic dipeptide design to the toolkit — with exceptional stability that surpasses many linear peptide gels. As cancer therapy moves toward localized and sustained drug delivery to reduce systemic side effects, materials like this could become important components of next-generation treatment strategies.
Questions still open
- How does the 5FU-loaded hydrogel perform in animal tumor models compared to free 5FU?
- Can this dipeptide hydrogel be loaded with other chemotherapy drugs or drug combinations?
- Would the hydrogel be injectable at the tumor site, or would it need to be surgically implanted?
Common questions
How can just two amino acids form a stable gel?
Why is sustained drug release better than giving the drug all at once?
Read the original research
S-Benzyl cysteine based cyclic dipeptide super hydrogelator: Enhancing efficacy of an anticancer drug via sustainable release.
Journal of peptide science : an official publication of the European Peptide Society, 28(8), e3403
Citation
Ghosh, Saswati; Nag, Sayoni; Saha, Krishna Das; Banerji, Biswadip. (2022). S-Benzyl cysteine based cyclic dipeptide super hydrogelator: Enhancing efficacy of an anticancer drug via sustainable release.. Journal of peptide science : an official publication of the European Peptide Society, 28(8), e3403. https://doi.org/10.1002/psc.3403